SIGLEC10 and acute myeloid leukemia: Notably, SIGLEC10, the receptor of CD52, was also associated with the adverse prognosis of AML (log-rank p = 0.04; Fig. 6H), further suggesting the important role of CD52-triggered signaling in AML progression.